m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04189)
Name
RetinoStat
Synonyms
AngiStat; XiaGen; Cardiovascular disease therapy, Oxford Biomedica; Gene therapy (HRE), Oxford Biomedica; Angiostatin/endostatin gene therapy (LentiVector, AMD), Oxford Biomedica
    Click to Show/Hide
Status
Phase 2
TTD Drug ID
D0RD0Y
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Endostatin (COL18A1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Endostatin (COL18A1) is a therapeutic target for RetinoStat. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of RetinoStat through regulating the expression of Endostatin (COL18A1). [1], [2]
References
Ref 1 A dynamic N(6)-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. Cell Res. 2018 Nov;28(11):1062-1076. doi: 10.1038/s41422-018-0097-4. Epub 2018 Oct 8.
Ref 2 Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. doi: 10.1038/s41573-019-0028-1.